fluorouracil and Brain Neoplasms studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.

Research Excerpts

Excerpt	Relevance	Reference
"Patients with breast cancer and central nervous system (CNS) metastases received whole-brain radiotherapy concurrently with capecitabine (1,000 mg/m(2) per day for 14 consecutive days), followed by concomitant capecitabine (2,000 mg/m(2) per day for 2 weeks followed by a 1-week break) and sunitinib (37."	9.20	A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer. ( Elledge, R; Foreman, C; Hilsenbeck, SG; Niravath, P; Rimawi, M; Rodriguez, A; Tham, YL; Wang, T, 2015)
"We report a phase I study to examine the pharmacokinetics, safety, and recommended dosage of weekly intravenous bolus 5-fluorouracil (5-FU) in children and young adults with recurrent ependymoma."	9.20	Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. ( Boulos, N; Daryani, VM; Gajjar, A; Gilbertson, RJ; Onar-Thomas, A; Orr, BA; Stewart, CF; Turner, DC; Wright, KD, 2015)
"In this study, we investigated the effect of lapatinib plus capecitabine treatment in HER2-positive breast cancer patients with brain metastasis."	9.19	Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Socie ( Akman, T; Alici, S; Arslan, UY; Boruban, C; Coskun, U; Dayan, A; Demir, L; Durnalı, AG; Elkiran, ET; Geredeli, C; Gumusay, O; Inal, A; Inanc, M; Isikdogan, A; Kaplan, MA; Koca, D; Kocer, M; Kucukoner, M; Oksuzoglu, B; Ozdemir, NY; Sener, N; Suner, A; Tarhan, MO; Urakci, Z; Yildiz, R, 2014)
"In this single-arm phase 2, open-label, multicentre study, eligible patients had HER2-positive metastatic breast cancer with brain metastases not previously treated with WBRT, capecitabine, or lapatinib."	9.17	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. ( Bachelot, T; Campone, M; Cropet, C; Curé, H; Dalenc, F; Diéras, V; Domont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Jimenez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Pierga, JY; Romieu, G, 2013)
"The Lapatinib Expanded Access Program (LEAP) was designed to provide access to lapatinib plus capecitabine for HER2-positive metastatic breast cancer patients who previously received an anthracycline, a taxane, and a trastuzumab and had no other treatment options."	9.14	An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. ( Capri, G; Chang, J; Chen, SC; Conte, P; Cwiertka, K; De Placido, S; Jerusalem, G; Jiang, Z; Johnston, S; Kaufman, B; Link, J; Oliva, C; Parikh, R; Preston, A; Ro, J; Rosenlund, J; Schütte, J; Selzer, M; Zembryki, D, 2010)
"Previous preclinical studies suggested that concurrent capecitabine and radiation could be an effective new treatment modality for glioblastoma (GBM)."	9.14	Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome. ( Cantor, A; Fathallah-Shaykh, HM; Fiveash, J; Grunda, JM; Johnson, MR; Nabors, LB; Palmer, CA, 2010)
" The strategy was evaluated initially to provide localized and sustained delivery of the radiosensitizer 5-fluorouracil (5-FU) after patients underwent surgical resection of malignant glioma."	9.11	Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. ( Benoit, JP; Boisdron-Celle, M; Delhaye, M; Faisant, N; Fournier, D; Jadaud, E; Menei, P; Michalak, S, 2004)
" In this study, this method was used to provide localized and sustained delivery of 5-fluorouracil (5-FU) after the surgical resection of glioblastoma."	9.09	Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study. ( Benoit, JP; Fournier, D; Gamelin, E; Guy, G; Hayek, G; Jadaud, E; Menei, P; Mercier, P; Saint-André, JP; Venier, MC, 1999)
"Fourteen patients with malignant gliomas were entered on a phase II study of 5-fluorouracil 300-370 mg/m2 plus folinic acid 200 mg/m2 x 5 days q4 weeks."	9.08	A phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults. ( Dahrouge, S; Soltys, K; Stewart, DJ, 1995)
"In the present study, we investigated the clinical outcome of patients with brain metastases (BMs) from human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) treated with lapatinib and capecitabine (LC)."	7.77	Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. ( Cognetti, F; Crinò, L; Fabi, A; Foglietta, J; Giannarelli, D; Gori, S; Metro, G; Mottolese, M; Papaldo, P; Russillo, M; Stocchi, L; Vidiri, A, 2011)
"The global lapatinib expanded access programme provided access to lapatinib combined with capecitabine for women with HER2-positive metastatic breast cancer (MBC) who previously received anthracycline, taxane and trastuzumab."	7.76	Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. ( Ashley, S; Bhatti, R; Camburn, T; Chan, S; Davidson, N; Johnston, SR; Miles, D; Nouras, H; Shehata, M; Sutherland, S; Wardley, A, 2010)
"We report a durable (12-month) response to capecitabine monotherapy, shown clinically, by MRI, and by cerebrospinal fluid analysis, in a patient with leptomeningeal metastasis from breast cancer."	7.72	Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. ( Remer, SE; Rogers, LR; Tejwani, S, 2004)
"We report a case in which brain metastases originating from breast cancer responded to treatment with oral capecitabine."	7.71	Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. ( Royce, ME; Schomer, DF; Theriault, RL; Wang, ML; Yung, WK, 2001)
" In this study the effects of intracarotid infusion of LTE4 on blood-tumor barrier (BTB) permeability for intravenously administered 14C-aminoisobutyric acid, 14C-5-fluorouracil (5-FU) 14C-sucrose and 3H-methotrexate (MTX) were examined in C6 gliomas of rats."	7.69	Leukotriene E4 selectively increase the delivery of methotrexate to the C6 gliomas in rats. ( Chio, CC; Lin, MT; Lin, SJ, 1995)
"Twenty-eight evaluable children with the diagnosis of brain stem glioma were treated with 5-fluorouracil and CCNU before posterior fossa irradiation (5500 rads); during irradiation, the children received hydroxyurea and misonidazole."	7.67	5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. ( Allen, J; Edwards, MS; Levin, VA; Ortega, J; Vestnys, P; Wara, WM, 1984)
"The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine."	7.67	Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. ( Berger, M; Chamberlain, M; Choucair, A; Da Silva, V; Davis, RL; Levin, VA; Liu, HC; Murovic, J; Phuphanich, S; Seager, M, 1986)
"Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine."	7.67	Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988)
"Patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and cranial radiotherapy were included."	6.76	Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. ( Campone, M; Eierman, W; Greil, R; Kaufman, B; Lane, SR; Lin, NU; Rubin, SD; Steplewski, K; Winer, EP; Zembryki, D, 2011)
"Eligible patients had HER2+ breast cancer, progressive brain metastases, prior trastuzumab, and cranial radiotherapy."	6.74	Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. ( Blum, JL; Brufsky, A; Christodoulou, C; Ciruelos, E; Dharan, B; Diéras, V; Gori, S; Greil, R; Lin, NU; Liu, MC; Loibl, S; Lossignol, D; Oliva, C; Paoletti, P; Paul, D; Roché, H; Roychowdhury, D; Rubin, SD; Stemmler, HJ; Steplewski, K; Wardley, A; Winer, EP; Yardley, D; Zembryki, D, 2009)
"Capecitabine was administered at a dose of 1,250 mg/m(2) bid for 14 consecutive days in 3-week cycles, with dose modifications if necessary."	6.73	Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. ( Altorjai, G; Bartsch, R; Gnant, M; Mader, RM; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC, 2007)
"Celecoxib was never discontinued for toxicity."	6.73	Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008)
"For patients who have significant residual tumor after resection or relapse after radiation, the proper chemotherapy regimen has not yet been identified."	6.72	Effectiveness of novel combination chemotherapy, consisting of 5-fluorouracil, vincristine, cyclophosphamide and etoposide, in the treatment of low-grade gliomas in children. ( Ahn, SD; Ghim, TT; Goo, HW; Khang, SK; Kim, YJ; Lee, MJ; Park, JB; Ra, YS; Song, JS, 2006)
"AcF is highly active in breast cancer with acceptable toxicities and can be used before alkylating agent-based high-dose therapy."	6.68	Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. ( Cameron, DA; Gabra, H; Lee, LE; Leonard, RC; Mackay, J, 1996)
"Lapatinib is a dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR1/ErbB1) and HER2/ErbB2."	6.45	[Lapatinib treatment-option in trastuzumab-resistant breast cancer]. ( Pikó, B, 2009)
"Breast cancer brain metastases (BCBM) are challenging complications that respond poorly to systemic therapy."	5.42	Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. ( Balyan, R; Lockman, PR; Morikawa, A; Murphy, CG; Peereboom, DM; Samala, R; Seidman, AD; Simmons, A; Smith, QR; Steeg, PS; Tabar, V; Thorsheim, HR; Weil, RJ, 2015)
"Capecitabine was orally administered to mouse returning an unbound brain-to-blood ratio (Kp,uu,brain) at 0."	5.42	Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis? ( Bai, Y; Cheng, Z; Li, S; Lv, J; Xie, L; Yan, Y; Zhang, J; Zhang, L; Zhang, X; Zhong, W, 2015)
"Capecitabine was administered orally at 628mg/m / 2 twice daily on days 1-21, and paclitaxel 80 mg/m2 was injected on days 1, 8, and 15."	5.38	[A case of breast cancer with brain metastases responding to paclitaxel and capecitabine therapy]. ( Imai, A; Mizuta, N; Nakatsukasa, K; Sakaguchi, K; Taguchi, T, 2012)
"In patients with HER2-positive breast cancer, cerebral metastasis sometimes occurs even if the breast tumor and liver/lung metastasis are controlled with trastuzumab."	5.38	[A case of HER2-positive breast cancer receiving lapatinib+capecitabine chemotherapy with ventriculoperitoneal shunting for hydrocephalus associated with brain metastases]. ( Kato, Y; Kawamura, H; Makino, T; Nishina, M; Yokoyama, E, 2012)
"From January 2003 to March 2005, five breast cancer patients with brain metastases were referred for WBRT with concurrent capecitabine."	5.35	Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. ( Campana, F; Castro Pena, P; Chargari, C; Cottu, PH; Diéras, V; Fourquet, A; Kirova, YM; Pena, PC; Pierga, J, 2009)
"In this phase 3, open-label trial, 307 patients with metastatic MSI-H-dMMR colorectal cancer who had not previously received treatment were randomly assigned, in a 1:1 ratio, to receive pembrolizumab at a dose of 200 mg every 3 weeks or chemotherapy (5-fluorouracil-based therapy with or without bevacizumab or cetuximab) every 2 weeks."	5.34	Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. ( André, T; Benavides, M; Bendell, J; de la Fouchardiere, C; Diaz, LA; Elez, E; Farooqui, MZH; Garcia-Carbonero, R; Gibbs, P; Jensen, BV; Jensen, LH; Kim, TW; Le, DT; Marinello, P; Punt, C; Rivera, F; Shiu, KK; Smith, D; Van Cutsem, E; Yang, P; Yoshino, T, 2020)
"5-Fluorouracil (5-FU) is a potent antimetabolite used for chemotherapy of gastrointestinal (GI), breast, and head and neck malignancies."	5.31	Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. ( Buchsbaum, DJ; Gillespie, GY; Miller, CR; Williams, CR, 2002)
"5-Fluorouracil (5-FU) was selected for encapsulation, because this hydrophilic and antimetabolic drug is not directly neurotoxic and does not readily cross the blood-brain barrier."	5.29	Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. ( Benoit, JP; Boisdron-Celle, M; Croué, A; Guy, G; Menei, P, 1996)
"Carmofur, 1-hexylcarbamoyl-5-fluorouracil (HCFU) is an antineoplastic drug, which has been in clinics in Japan since 1981 for the treatment of colorectal cancer."	5.22	Versatile use of Carmofur: A comprehensive review of its chemistry and pharmacology. ( Islam, MM; Mirza, SP, 2022)
"Patients with breast cancer and central nervous system (CNS) metastases received whole-brain radiotherapy concurrently with capecitabine (1,000 mg/m(2) per day for 14 consecutive days), followed by concomitant capecitabine (2,000 mg/m(2) per day for 2 weeks followed by a 1-week break) and sunitinib (37."	5.20	A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer. ( Elledge, R; Foreman, C; Hilsenbeck, SG; Niravath, P; Rimawi, M; Rodriguez, A; Tham, YL; Wang, T, 2015)
"We report a phase I study to examine the pharmacokinetics, safety, and recommended dosage of weekly intravenous bolus 5-fluorouracil (5-FU) in children and young adults with recurrent ependymoma."	5.20	Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. ( Boulos, N; Daryani, VM; Gajjar, A; Gilbertson, RJ; Onar-Thomas, A; Orr, BA; Stewart, CF; Turner, DC; Wright, KD, 2015)
"In this study, we investigated the effect of lapatinib plus capecitabine treatment in HER2-positive breast cancer patients with brain metastasis."	5.19	Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Socie ( Akman, T; Alici, S; Arslan, UY; Boruban, C; Coskun, U; Dayan, A; Demir, L; Durnalı, AG; Elkiran, ET; Geredeli, C; Gumusay, O; Inal, A; Inanc, M; Isikdogan, A; Kaplan, MA; Koca, D; Kocer, M; Kucukoner, M; Oksuzoglu, B; Ozdemir, NY; Sener, N; Suner, A; Tarhan, MO; Urakci, Z; Yildiz, R, 2014)
"In this single-arm phase 2, open-label, multicentre study, eligible patients had HER2-positive metastatic breast cancer with brain metastases not previously treated with WBRT, capecitabine, or lapatinib."	5.17	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. ( Bachelot, T; Campone, M; Cropet, C; Curé, H; Dalenc, F; Diéras, V; Domont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Jimenez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Pierga, JY; Romieu, G, 2013)
"The Lapatinib Expanded Access Program (LEAP) was designed to provide access to lapatinib plus capecitabine for HER2-positive metastatic breast cancer patients who previously received an anthracycline, a taxane, and a trastuzumab and had no other treatment options."	5.14	An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. ( Capri, G; Chang, J; Chen, SC; Conte, P; Cwiertka, K; De Placido, S; Jerusalem, G; Jiang, Z; Johnston, S; Kaufman, B; Link, J; Oliva, C; Parikh, R; Preston, A; Ro, J; Rosenlund, J; Schütte, J; Selzer, M; Zembryki, D, 2010)
"Previous preclinical studies suggested that concurrent capecitabine and radiation could be an effective new treatment modality for glioblastoma (GBM)."	5.14	Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome. ( Cantor, A; Fathallah-Shaykh, HM; Fiveash, J; Grunda, JM; Johnson, MR; Nabors, LB; Palmer, CA, 2010)
"To evaluate the antitumor activity and toxicity of 5-fluorouracil (FU)/leucovorin (LV) and capecitabine (C) given with either oxaliplatin (OX) or camptothecin (CPT-11) in the treatment of chemotherapy naive patients with metastatic colorectal cancer."	5.13	Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. ( Bisegna, R; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F, 2008)
"A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer."	5.12	Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. ( Arun, B; Broglio, K; Buchholz, T; Francis, D; Groves, M; Hortobagyi, GN; Meyers, C; Rivera, E; Valero, V; Yin, G, 2006)
"A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma)."	5.12	Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. ( Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E, 2007)
" The strategy was evaluated initially to provide localized and sustained delivery of the radiosensitizer 5-fluorouracil (5-FU) after patients underwent surgical resection of malignant glioma."	5.11	Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. ( Benoit, JP; Boisdron-Celle, M; Delhaye, M; Faisant, N; Fournier, D; Jadaud, E; Menei, P; Michalak, S, 2004)
" In this study, this method was used to provide localized and sustained delivery of 5-fluorouracil (5-FU) after the surgical resection of glioblastoma."	5.09	Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study. ( Benoit, JP; Fournier, D; Gamelin, E; Guy, G; Hayek, G; Jadaud, E; Menei, P; Mercier, P; Saint-André, JP; Venier, MC, 1999)
"Fourteen patients with malignant gliomas were entered on a phase II study of 5-fluorouracil 300-370 mg/m2 plus folinic acid 200 mg/m2 x 5 days q4 weeks."	5.08	A phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults. ( Dahrouge, S; Soltys, K; Stewart, DJ, 1995)
"In an attempt to improve the primary treatment of malignant gliomas we used a concomitant 6-week course of chemoradiotherapy with 5 fluorouracil (5 FU) and hydroxyurea (HU) in 24 adults with anaplastic astrocytoma (AA) (7 cases) or glioblastomas (GLB) (17 cases)."	5.07	Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas. ( Armand, JP; Cioloca, C; Constans, JP; Cvitkovic, FB; Haie-Meder, C; Maugis, N; Papadimitrakopoulou, V, 1993)
"From August 1987 through September 1989, 25 patients with either anaplastic astrocytoma (8 patients) or glioblastoma multiforme (17 patients) were entered into a Phase I trial of combined intra-arterial 5-fluorouracil (5-FU) and external beam radiation therapy."	5.07	Phase I/II trial of superselective arterial 5-FU infusion with concomitant external beam radiation for patients with either anaplastic astrocytoma or glioblastoma multiforme. ( Constable, WC; Ferguson, R; Jane, JA; Kersh, CR; Kline, P; Larner, JM; Short, R, 1991)
"Thirty-seven patients with poor prognosis, metastatic breast cancer were treated with 5-fluorouracil, vinblastine, and Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) (FUVA) induction chemotherapy."	5.06	Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer. A Southwest Oncology Group Study. ( Ellis, GK; Goldberg, RS; Green, S; Livingston, RB; Schulman, S; Tranum, BL, 1989)
"Sixty-four patients with disseminated breast cancer were treated with an aggressive chemotherapy program of prednisone, methotrexate, 5-fluorouracil, Adriamycin (doxorubicin) and cyclophosphamide (PM-FAC)."	5.05	Aggressive adriamycin-containing regimen (PM-FAC) in estrogen receptor-negative disseminated breast cancer. Results of a Southwest Oncology Group trial. ( Flournoy, N; Livingston, RB; Mortimer, J; Stephens, RL, 1985)
"We report the cases of 2 breast cancer patients who received capecitabine(CAP)and concomitant anticonvulsant therapy with either phenytoin(PHT)or valproate(VPA)for brain metastasis."	3.80	[Effect of capecitabine therapy on the blood levels of antiepileptic drugs - report of two cases]. ( Ibayashi, Y; Jotoku, H; Takahashi, M; Takasaki, M; Tanaka, H; Watanabe, K, 2014)
" We describe the case of a colon cancer patient who underwent adjuvant treatment with capecitabine and oxaliplatin and was admitted to the hospital with seizures and brain edema."	3.80	[Blindness and symmetrical neurological deficit in a patient with colon cancer receiving adjuvant chemotherapy: is it always cancer?]. ( Fennig, S; Greenberg, G; Leshem, Y; Talianski, E; Wolf, I, 2014)
"Targeted therapy (lapatinib and/or trastuzumab) in combination with chemotherapy (capecitabine) is highly effective in metastatic lesions of the brain in breast cancer patients with overexpress HER-2/neu."	3.79	[Current possibilities of targeted therapy in the treatment of breast cancer with overexpression of HER-2/neu and metastatic lesions in the brain]. ( Gorbunova, VA; Moskvina, EA; Naskhletashvili, DR, 2013)
"Fourteen cases of metastatic brain tumors from lung cancer underwent biochemical modulation chemotherapy with daily administration of small doses of CDDP (5 or 10 mg/day) and continuous infusion of 5-FU (300 mg/day) for three tow six weeks."	3.78	[Effects of biochemical modulation chemotherapy with CDDP and 5-FU on metastatic brain tumor from lung cancer]. ( Hagiwara, Y; Kanayama, T; Moriuchi, S; Nakagawa, H; Yamada, M, 1997)
"In the present study, we investigated the clinical outcome of patients with brain metastases (BMs) from human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) treated with lapatinib and capecitabine (LC)."	3.77	Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. ( Cognetti, F; Crinò, L; Fabi, A; Foglietta, J; Giannarelli, D; Gori, S; Metro, G; Mottolese, M; Papaldo, P; Russillo, M; Stocchi, L; Vidiri, A, 2011)
"The global lapatinib expanded access programme provided access to lapatinib combined with capecitabine for women with HER2-positive metastatic breast cancer (MBC) who previously received anthracycline, taxane and trastuzumab."	3.76	Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. ( Ashley, S; Bhatti, R; Camburn, T; Chan, S; Davidson, N; Johnston, SR; Miles, D; Nouras, H; Shehata, M; Sutherland, S; Wardley, A, 2010)
"Since neural progenitor cells can engraft stably into brain tumors and differentiate along the neuronal and glial line, we tested the hypothesis that transplanted cytosine deaminase (CD)-expressing ST14A cells (an immortalized neural progenitor cell line) can convert locally 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU) and produce a regression of glioma tumors."	3.72	Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy. ( Barresi, V; Belluardo, N; Cattaneo, E; Condorelli, DF; Mudò, G; Sipione, S, 2003)
"Murine glioma 261 (Gl261) cells were transduced with an adenoviral vector (Adex-CAUPTK) encoding both uracil phosphoribosyltransferase and thymidine kinase genes which sensitise cells to 5-fluorouracil (5-FU) and ganciclovir (GC), respectively."	3.72	Local tumour irradiation enhances the anti-tumour effect of a double-suicide gene therapy system in a murine glioma model. ( Desaknai, S; Esik, O; Hamada, H; Lumniczky, K; Safrany, G, 2003)
"To evaluate an intracranial polymer implant containing bromodeoxyuridine (BrdUrd) and N-(phosphonacetyl)-L-aspartic acid (PALA) in combination with external beam radiotherapy (EBRT) in the treatment of a rat glioma."	3.72	Treatment of intracranial rat glioma model with implant of radiosensitizer and biomodulator drug combined with external beam radiotherapy. ( Lehnert, S; Li, Y; Owusu, A, 2004)
"We report a durable (12-month) response to capecitabine monotherapy, shown clinically, by MRI, and by cerebrospinal fluid analysis, in a patient with leptomeningeal metastasis from breast cancer."	3.72	Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. ( Remer, SE; Rogers, LR; Tejwani, S, 2004)
"We report a case in which brain metastases originating from breast cancer responded to treatment with oral capecitabine."	3.71	Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. ( Royce, ME; Schomer, DF; Theriault, RL; Wang, ML; Yung, WK, 2001)
" In this study the effects of intracarotid infusion of LTE4 on blood-tumor barrier (BTB) permeability for intravenously administered 14C-aminoisobutyric acid, 14C-5-fluorouracil (5-FU) 14C-sucrose and 3H-methotrexate (MTX) were examined in C6 gliomas of rats."	3.69	Leukotriene E4 selectively increase the delivery of methotrexate to the C6 gliomas in rats. ( Chio, CC; Lin, MT; Lin, SJ, 1995)
" We have treated 18 recurrent glioma patients with high dose methotrexate (HDMTX) plus 5-fluorouracil (5FU)."	3.68	Neoadjuvant chemotherapy in the treatment of recurrent glioblastomas (GBM). ( Boiardi, A; Croci, D; Perego, E; Silvani, A; Solero, CL, 1992)
"Twenty-eight evaluable children with the diagnosis of brain stem glioma were treated with 5-fluorouracil and CCNU before posterior fossa irradiation (5500 rads); during irradiation, the children received hydroxyurea and misonidazole."	3.67	5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. ( Allen, J; Edwards, MS; Levin, VA; Ortega, J; Vestnys, P; Wara, WM, 1984)
"Four chemotherapeutic agents (cyclophosphamide, 5-fluorouracil (5-FU), methotrexate (MTX), and bleomycin) were given intravenously to rats harboring the avian sarcoma virus-induced glioma."	3.67	Chemotherapeutic agent permeability to normal brain and delivery to avian sarcoma virus-induced brain tumors in the rodent: observations on problems of drug delivery. ( Barnett, PA; Frenkel, EP; Neuwelt, EA, 1984)
"The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine."	3.67	Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. ( Berger, M; Chamberlain, M; Choucair, A; Da Silva, V; Davis, RL; Levin, VA; Liu, HC; Murovic, J; Phuphanich, S; Seager, M, 1986)
"Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine."	3.67	Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988)
"11 patients (age 36-60 years) with breast cancer and CT-scan documented brain metastases (BM) were treated with hormonochemotherapy: 5-fluorouracil 500 mg/m2 i."	3.66	[Successful treatment of brain metastases in breast cancer with blood-brain barrier-impervious cytostatics and hormones]. ( Bleichner, F; Mende, S; Meuret, G; Stoeter, P, 1983)
"Decrease of circulating tumor cells (CTC) during treatment is an independent prognostic factor in metastatic breast cancer (MBC)."	2.78	Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial. ( Bachelot, T; Bidard, FC; Campone, M; Cropet, C; Curé, H; Dalenc, F; Dômont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Mahier Aït-Oukhatar, C; Pierga, JY; Romieu, G; Tresca, P, 2013)
"Patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and cranial radiotherapy were included."	2.76	Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. ( Campone, M; Eierman, W; Greil, R; Kaufman, B; Lane, SR; Lin, NU; Rubin, SD; Steplewski, K; Winer, EP; Zembryki, D, 2011)
"Eligible patients had HER2+ breast cancer, progressive brain metastases, prior trastuzumab, and cranial radiotherapy."	2.74	Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. ( Blum, JL; Brufsky, A; Christodoulou, C; Ciruelos, E; Dharan, B; Diéras, V; Gori, S; Greil, R; Lin, NU; Liu, MC; Loibl, S; Lossignol, D; Oliva, C; Paoletti, P; Paul, D; Roché, H; Roychowdhury, D; Rubin, SD; Stemmler, HJ; Steplewski, K; Wardley, A; Winer, EP; Yardley, D; Zembryki, D, 2009)
"Capecitabine was administered at a dose of 1,250 mg/m(2) bid for 14 consecutive days in 3-week cycles, with dose modifications if necessary."	2.73	Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. ( Altorjai, G; Bartsch, R; Gnant, M; Mader, RM; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC, 2007)
"Celecoxib was never discontinued for toxicity."	2.73	Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008)
"For patients who have significant residual tumor after resection or relapse after radiation, the proper chemotherapy regimen has not yet been identified."	2.72	Effectiveness of novel combination chemotherapy, consisting of 5-fluorouracil, vincristine, cyclophosphamide and etoposide, in the treatment of low-grade gliomas in children. ( Ahn, SD; Ghim, TT; Goo, HW; Khang, SK; Kim, YJ; Lee, MJ; Park, JB; Ra, YS; Song, JS, 2006)
"Thirty patients with recurrent primary brain tumors were treated with a combination of 5-fluorouracil and leucovorin."	2.68	Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor. ( Buckner, JC; Cascino, TL; Goldberg, RM; Kuross, SA; Levitt, R; Morton, RF; O'Fallon, JR; Scheithauer, BW; Veeder, MH; Wiesenfeld, M, 1996)
"AcF is highly active in breast cancer with acceptable toxicities and can be used before alkylating agent-based high-dose therapy."	2.68	Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. ( Cameron, DA; Gabra, H; Lee, LE; Leonard, RC; Mackay, J, 1996)
"Twenty-five patients with metastatic breast cancer were studied."	2.67	4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. ( Affronti, ML; Bast, RC; Eggleston, S; Johnston, C; Jones, RB; Rosner, GL; Ross, M; Shpall, EJ; Tepperburg, M; Vandermark, R, 1991)
"Significant improvement in dysphagia was recorded in 76% patients with complete response in 47 cases ranging from 6 to 27 months."	2.67	The role of intraluminal radiotherapy and concurrent 5-fluorouracil infusion in the management of carcinoma esophagus: a pilot study. ( Desai, PB; Deshpande, R; Dinshaw, KA; Malliat, MK; Pendse, AM; Sharma, V; Telang, CS; Vege, SS, 1991)
"Among 2636 patients with stage III colon cancer treated with FOLFOX, MMR status was available for 2501."	2.58	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. ( Alberts, SR; Folprecht, G; Goldberg, RM; Julie, C; Laurent-Puig, P; Le Malicot, K; Meyers, JP; Mini, E; Sargent, DJ; Shi, Q; Sinicrope, FA; Smyrk, TC; Tabernero, J; Taieb, J; Van Laethem, JL; Zaanan, A; Zawadi, A, 2018)
"Sinonasal undifferentiated carcinoma (SNUC) represents less than 1% of all malignancies."	2.53	Management of sinonasal undifferentiated carcinoma with intracerebral invasion: Clinical experience at a single institution and review of the literature. ( Clauditz, T; Knecht, R; Laban, S; Muenscher, A; Schafhausen, P; Tribius, S; Veldhoen, S; Zielinski, V, 2016)
"The incidence of brain metastases from breast cancer is increasing with diagnosis and therapeutics progress, especially with systemic therapies."	2.50	[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer]. ( Cao, KI; Kirova, YM, 2014)
"Prevalence of brain metastases is increasing in breast cancer."	2.49	[Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies]. ( Bachelot, T; Bonneterre, J; Gilabert, M; Gonçalves, A; Heudel, P; Labidi-Gally, I; Le Rhun, E; Pierga, JY, 2013)
"Breast cancer brain metastases (BCBMs) are the second most frequent secondary central nervous system metastases following those associated with non-small-cell lung cancer."	2.48	New insights and emerging therapies for breast cancer brain metastases. ( Lim, E; Lin, NU, 2012)
"Lapatinib is a dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR1/ErbB1) and HER2/ErbB2."	2.45	[Lapatinib treatment-option in trastuzumab-resistant breast cancer]. ( Pikó, B, 2009)
"We observed a case of multiple brain metastases in an EOC patient after complete response of a pelvic recurrence to platinum/paclitaxel chemotherapy."	2.42	Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. ( Cesák, T; Kohlová, T; Melichar, B; Nová, M; Urminská, H, 2004)
"The role of chemotherapy in breast cancer brain metastases is not clearly defined; the results of the 8 trials found in the literature are reported."	2.41	Chemotherapy for breast cancer brain metastases. ( Fenner, MH; Possinger, K, 2002)
"Patients with cancer commonly suffer neurologic disabilities."	2.37	Neurologic complications of systemic cancer. ( Patchell, RA; Posner, JB, 1985)
"Treatment options for locally advanced rectal cancer have continued to consist largely of chemotherapy, chemoradiation, and/or surgical resection."	1.56	Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. ( Cho, M; Damle, N; Dayyani, F; Demisse, R; Eng, C; Fakih, M; Gholami, S; Gong, J; Halabi, W; Ji, J; Kim, E; Liu, J; Louie, R; McKenny, M; Monjazeb, A; Oesterich, L; Tam, K, 2020)
"Distant metastasis still remained a major concern in pCR patients following nCRT and TME."	1.51	Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors. ( Chi, P; Huang, Y; Lin, H; Lu, X; Sun, Y; Wu, X; Zhang, Y, 2019)
"Breast cancer brain metastases (BCBM) are challenging complications that respond poorly to systemic therapy."	1.42	Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. ( Balyan, R; Lockman, PR; Morikawa, A; Murphy, CG; Peereboom, DM; Samala, R; Seidman, AD; Simmons, A; Smith, QR; Steeg, PS; Tabar, V; Thorsheim, HR; Weil, RJ, 2015)
"Capecitabine was orally administered to mouse returning an unbound brain-to-blood ratio (Kp,uu,brain) at 0."	1.42	Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis? ( Bai, Y; Cheng, Z; Li, S; Lv, J; Xie, L; Yan, Y; Zhang, J; Zhang, L; Zhang, X; Zhong, W, 2015)
"Irinotecan has synergism with 5-fluorouracil and shows efficacy in advanced breast cancer."	1.42	Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane. ( Cho, JM; Go, SI; Jeon, KN; Kang, JH; Kang, MH; Kim, HG; Kim, MJ; Lee, A; Lee, GW; Lee, JH; Lee, US; Lee, WS, 2015)
"Two patients presented with brain metastases, while one demonstrated lymphangitic spread to lungs."	1.40	A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. ( Calkins, SM; Cinar, P; Kelley, RK; Venook, AP, 2014)
"Most (90%) patients with brain metastases were diagnosed within 24 months of surgery."	1.39	Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. ( Ajani, JA; Bhutani, MS; Blum, MA; Campagna, MC; Correa, AM; Hofstetter, WL; Komaki, R; Lee, JH; Maru, DM; Rice, DC; Skinner, H; Sudo, K; Swisher, S; Taketa, T; Wadhwa, R; Weston, B, 2013)
" Survival benefit is dose dependent for both vector and 5-FC, and as few as 4 cycles of 5-FC dosing after Toca 511 therapy provides significant survival advantage."	1.38	Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. ( Amundson, KK; Buckley, T; Burnett, R; Chen, CI; Daublebsky, V; Galvão da Silva, AP; Gruber, HE; Gunzburg, W; Hlavaty, J; Ibañez, CE; Jolly, DJ; Kasahara, N; Lin, AH; Lopez Espinoza, F; Martin, B; Ostertag, D; Perez, OD; Pettersson, PL; Robbins, JM; Valenta, DT, 2012)
"Capecitabine was administered orally at 628mg/m / 2 twice daily on days 1-21, and paclitaxel 80 mg/m2 was injected on days 1, 8, and 15."	1.38	[A case of breast cancer with brain metastases responding to paclitaxel and capecitabine therapy]. ( Imai, A; Mizuta, N; Nakatsukasa, K; Sakaguchi, K; Taguchi, T, 2012)
"The majority of brain metastases result from lung cancer, but the metastatic mechanism remains unclear."	1.38	Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties. ( Cho, MH; Choi, KC; Kim, SU; Kim, YB; Lee, HJ; Yi, BR, 2012)
"In patients with HER2-positive breast cancer, cerebral metastasis sometimes occurs even if the breast tumor and liver/lung metastasis are controlled with trastuzumab."	1.38	[A case of HER2-positive breast cancer receiving lapatinib+capecitabine chemotherapy with ventriculoperitoneal shunting for hydrocephalus associated with brain metastases]. ( Kato, Y; Kawamura, H; Makino, T; Nishina, M; Yokoyama, E, 2012)
"Moreover, circulating tumor cells were demonstrated by flow cytometry."	1.38	[Severe hemorrhage in a patient with metastatic colorectal cancer - case 8/2012]. ( Horger, M; Jaschonek, K; Kanz, L; Kopp, HG; Kurth, R; Mayer, F; Orgel, M, 2012)
"From January 2003 to March 2005, five breast cancer patients with brain metastases were referred for WBRT with concurrent capecitabine."	1.35	Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. ( Campana, F; Castro Pena, P; Chargari, C; Cottu, PH; Diéras, V; Fourquet, A; Kirova, YM; Pena, PC; Pierga, J, 2009)
"Five months later, diffuse and multiple brain metastases relapsed, and second-line chemotherapy did not respond well, and finally he was died 3 months after palliative care."	1.35	[A case of a 14-month survival patient on advanced esophageal cancer with uncontrolled brain metastasis completely responding to nedaplatin, adriamycin, plus 5-FU (NAF) therapy]. ( Doi, T; Hoshi, M; Iijima, S; Kato, A; Kato, T; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Miyo, M; Ooshima, S; Sakamoto, T, 2009)
"Lack of effective therapy of primary brain tumors has promoted the development of novel experimental approaches utilizing oncolytic viruses combined with gene therapy."	1.34	Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. ( Gillespie, GY; Guffey, MB; Luckett, WS; Markert, JM; Meleth, S; Parker, JN; Whitley, RJ, 2007)
"Female breast cancer is one of the major causes of death among women while male breast cancer is relatively uncommon and accounts for about 1% of all breast cancers in both sexes."	1.34	Male breast cancer with mandibular metastasis. A case report. ( Amaddeo, P; Barbaglio, A; Faldi, F; Fontana, S; Ghilardi, R; Pericotti, S, 2007)
"The incidence of brain metastases from breast cancer seems to be increasing with the improvement of systemic control and survival prolongation."	1.33	[Clinical analysis of 67 patients with brain metastases from breast cancer]. ( Feng, FY; He, J; Wang, XY; Xing, PY; Zhang, P, 2005)
"The most common sites of distant recurrence are represented by lung, liver and bone while brain and breast metastases are rare."	1.33	Successful outcome after combined chemotherapeutic and surgical management in a case of esophageal cancer with breast and brain relapse. ( Cossu Rocca, P; Costantino, S; Fadda, GM; Farris, A; Pinna, MA; Piredda, G; Putzu, C; Sanna, G; Santeufemia, DA; Sarobba, MG, 2006)
"In order to treat malignant brain tumors by local delivery of antineoplastic agents, the feasibility of 5-fluorouracil (5-FU)-sustained release biodegradable microspheres with a novel material, poly(methylidene malonate 2."	1.32	Development of novel 5-FU-loaded poly(methylidene malonate 2.1.2)-based microspheres for the treatment of brain cancers. ( Benoit, JP; Breton, P; Colin, N; Fournier, E; Passirani, C; Sagodira, S, 2004)
"The development of brain metastases was related to young age (P = 0."	1.32	Brain metastases from breast cancer: identification of a high-risk group. ( Burrell, HC; Chan, SY; Cheung, KL; Cornford, EJ; Evans, AJ; Gutteridge, E; Hornbuckle, J; James, JJ; Pinder, SE; Robertson, JF, 2004)
"In the United States, tumors of the central nervous system remain the third leading cancer-related cause of death in young adults with a median survival time of < 1 year."	1.31	Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. ( Bharara, S; Blanquicett, C; Buchsbaum, DJ; Diasio, RB; Gillespie, GY; Johnson, MR; Miller, CR; Nabors, LB, 2002)
"5-Fluorouracil (5-FU) is a potent antimetabolite used for chemotherapy of gastrointestinal (GI), breast, and head and neck malignancies."	1.31	Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. ( Buchsbaum, DJ; Gillespie, GY; Miller, CR; Williams, CR, 2002)
"A case of breast cancer metastasis to the skin and bone 13 years after, and to the brain 17 years after mastectomy in a 54-year-old woman, is reported."	1.30	[A case of breast cancer metastasis to the skin and bone 13 years after, and to the brain 17 years after mastectomy]. ( Fujino, H; Itoshima, T; Kasamatsu, T; Kodama, M; Morita, Y; Yamamoto, H; Yamamoto, T, 1997)
"In this retrospective study, 162 breast cancer patients were analysed in whom brain metastases had been diagnosed clinically between 1969 and 1995 at a single institution."	1.30	Brain metastases in breast cancer: prognostic factors and management. ( Budach, V; Dörken, B; Lentzsch, S; Reichardt, P; Weber, F, 1999)
"This report concerns four patients with brain metastases from breast carcinoma treated initially by systemic chemotherapy."	1.29	[Chemotherapy in the treatment of brain metastases of breast cancers]. ( Bastit, P; Chevallier, B; Couteau, C, 1994)
"In ten multiple metastatic brain tumors, three complete responses, two partial responses, one minor response and four non-responses were observed on MRI."	1.29	[Chemotherapy for metastatic brain tumors with CDDP and other agents: correlation between chemotherapeutic effects and the results of in vitro chemosensitivity tests using collagen gel-embedded culture combined with computerized image analysis in metastat ( Hagiwara, Y; Kanayama, T; Kobayashi, H; Koezuka, M; Miyawaki, Y; Nakagawa, H; Tokiyoshi, K; Tsuruzono, K; Yamada, M, 1994)
"5-Fluorouracil (5-FU) was selected for encapsulation, because this hydrophilic and antimetabolic drug is not directly neurotoxic and does not readily cross the blood-brain barrier."	1.29	Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. ( Benoit, JP; Boisdron-Celle, M; Croué, A; Guy, G; Menei, P, 1996)
"In a patient with akinetic mutism, extensive circumscribed bilateral lesions in the precentral part of the centrum semiovale, due to delayed necrotizing leucoencephalopathy after combined intravenous polychemotherapy and radiation, were found at autopsy."	1.28	Akinetic mutism in bilateral necrotizing leucoencephalopathy after radiation and chemotherapy: electrophysiological and autopsy findings. ( Gütling, E; Kleihues, P; Landis, T, 1992)
"The authors treated 10 cases of malignant gliomas with intra-arterial chemotherapy after osmotic blood-brain barrier disruption."	1.28	[Intra-arterial chemotherapy of malignant glioma after osmotic blood-brain barrier disruption]. ( Hosoya, T; Nakai, O; Takahama, H; Takanashi, T; Yamada, K, 1989)
"Nineteen patients with brain tumors were orally administered 300 mg of UFT (a combination of FT and uracil with a molar ratio being 1:4) before operation and the concentrations of FT, 5-FU and Uracil in tumors and serum were measured by chemical assay."	1.27	[5-FU concentration in brain tumors after co-administration of FT and uracil]. ( Matsumoto, S; Nogaki, H; Tamaki, N; Taomoto, K, 1983)
"A combination chemotherapy regimen for brain tumors was developed, based on investigations of the survival of animals harboring the intracerebral 9L rat brain-tumor model and on analyses of their clonogenic tumor cells."	1.27	Improved treatment of a brain-tumor model. Part 2: Sequential therapy with BCNU and 5-fluorouracil. ( Dougherty, DV; Gerosa, MA; Rosenblum, ML; Wilson, CB, 1983)
"7 of 8 with brain metastases treated by the same modality gave complete remission."	1.27	[Combination therapy of advanced choriocarcinoma--an analysis of 60 patients]. ( Cai, SM; Ding, YQ; Wang, RY, 1986)
" Both dosage and releasing time can be adjusted."	1.27	[Treatment of malignant brain tumors with slowly releasing anticancer drug-polymer composites]. ( Himuro, H; Inoue, N; Kaetsu, I; Kitamura, K; Kubo, O; Sakairi, M; Tajika, T; Tajika, Y; Tohyama, T; Yoshida, M, 1986)
"Both EB and HRP penetrated the brain tumors but did not stain the normal brain tissues."	1.27	Hyperosmotic blood-brain barrier disruption in brains of rats with an intracerebrally transplanted RG-C6 tumor. ( Fukui, M; Inoue, T; Kitamura, K; Nagara, H; Nishio, S, 1987)
"A case of brain metastasis in ovarian cancer is reported."	1.27	[Metastatic brain tumor after chemotherapy of ovarian cancer]. ( Chen, JT; Fujimoto, I; Fukuda, K; Hasumi, K; Masubuchi, K; Sakamoto, A; Yamauchi, K, 1987)
"Primary chemotherapy of brain metastases yielded responses in 27 of 52 patients (52%) treated with Cytoxan (cyclophosphamide) (C), 5-fluorouracil (F) and prednisone (P); 19 of 35 (54%) receiving CFP-methotrexate (M) and vincristine (V); 3 of 7 (43%) treated with MVP, and 1 of 6 (17%) receiving Cytoxan plus Adriamycin (doxorubicin) (CA)."	1.27	Chemotherapy induces regression of brain metastases in breast carcinoma. ( Lane, WW; Nemoto, T; Rosner, D, 1986)
" If toxicity is intolerable, the dosage of CDDP and ADM was decreased in thirty percent."	1.27	[Therapeutic experiences of cis-diamminedichloroplatinum, adriamycin and 5-fluorouracil combination chemotherapy in advanced urothelial cancer, with special reference to adjuvant chemotherapy in invasive urothelial cancer]. ( Nakagawa, T; Nishimura, K; Ogawa, O; Taniguchi, T; Yoshimura, N, 1986)
"In those with metastatic brain tumors, the median survival time was 280 days, 1-year survival rate 43."	1.27	[Clinical application of a sustained release anticancer pellet]. ( Aoyama, I; Handa, H; Hashi, K; Kamijyo, Y; Mori, K; Oda, Y; Okumura, T; Tokuriki, Y; Yamashita, J, 1985)
" In vitro studies showed that 5-FC combined with CDase induced significant growth-inhibitory effects on the cultured glioma cells."	1.27	Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. ( Ito, T; Katsuragi, T; Kawamoto, K; Kawamura, Y; Matsumura, H; Nishiyama, T; Ohyama, A; Sakai, T; Yamamoto, N, 1985)
"77 microM) or moderately toxic (7."	1.27	Factors modifying cytotoxicity induced by 5-FU and hydroxyurea. ( Hoshino, T; Nagashima, T, 1985)
" After 5-fluorouracil treatment, 2 to 5 X 10(5) feeder cells were required to maximize surviving fractions for each drug concentration and to generate a biphasic dose-response curve."	1.26	Effect of feeder cell-released substances on the survival of clonogenic 9L cells after treatment with antimetabolites. ( Deen, DF; Weizsaecker, M, 1980)
"Eighty three patients suffering from brain tumors have been treated by anticancer pellets containing 5-FU, urokinase, mitomycin and BUdR in dimethylsiloxan (Silastic) for three years."	1.26	[Treatment of brain tumors with anticancer pellet--experimental and clinical study (author's transl)]. ( Handa, H; Hashi, K; Kieler, J; Kobayashi, A; Mori, K; Murata, T; Oda, Y; Tokuriki, Y; Uchida, Y, 1982)
"Human malignant melanoma was transplanted to the cheek pouch of immunosuppressed (corticosteroid-treated) hamsters."	1.26	Chemotherapy against human melanoma in the hamster cheek pouch. ( Dufour, FD; Mah, SG; Morton, DL; Okada, GT, 1980)

Research

Studies (286)

Authors

Clinical Trials (22)

Trial Overview

Trial Outcomes

Number of Participants Who Discontinued Study Treatment Due to an AE

Timeframe	Studies, this research(%)	All Research%
pre-1990	104 (36.36)	18.7374
1990's	44 (15.38)	18.2507
2000's	60 (20.98)	29.6817
2010's	70 (24.48)	24.3611
2020's	8 (2.80)	2.80

Authors	Studies
Alkış, ME	1
Turan, N	1
Alan, Y	1
Irtegun Kandemir, S	1
Buldurun, K	1
Baxter, NN	1
Kennedy, EB	1
Bergsland, E	1
Berlin, J	1
George, TJ	1
Gill, S	1
Gold, PJ	1
Hantel, A	1
Jones, L	1
Lieu, C	1
Mahmoud, N	1
Morris, AM	1
Ruiz-Garcia, E	1
You, YN	1
Meyerhardt, JA	1
Islam, MM	1
Mirza, SP	1
Sahu, KK	1
Pandey, D	1
Mishra, AK	1
O'Shea, J	1
Chen, Y	2
McGregor, B	1
Zhan, W	2
Saito, S	1
Yanagisawa, R	1
Minami, K	1
Uchida, E	1
Watanabe, T	1
Komori, K	1
Kurata, T	1
Nakamura, T	1
Sakashita, K	1
Demisse, R	1
Damle, N	1
Kim, E	1
Gong, J	1
Fakih, M	1
Eng, C	1
Oesterich, L	1
McKenny, M	1
Ji, J	1
Liu, J	1
Louie, R	1
Tam, K	1
Gholami, S	1
Halabi, W	1
Monjazeb, A	1
Dayyani, F	1
Cho, M	1
André, T	1
Shiu, KK	1
Kim, TW	1
Jensen, BV	1
Jensen, LH	1
Punt, C	1
Smith, D	1
Garcia-Carbonero, R	1
Benavides, M	1
Gibbs, P	1
de la Fouchardiere, C	1
Rivera, F	1
Elez, E	1
Bendell, J	1
Le, DT	1
Yoshino, T	1
Van Cutsem, E	1
Yang, P	1
Farooqui, MZH	1
Marinello, P	1
Diaz, LA	1
Huang, D	1
Wang, G	1
Mao, J	1
Liu, C	1
Fan, Z	1
Zhang, Y	2
Zhang, B	1
Zhao, Y	1
Dai, C	1
He, Y	1
Ma, H	1
Liu, G	1
Chen, X	1
Zhao, Q	1
Zaanan, A	1
Shi, Q	1
Taieb, J	1
Alberts, SR	1
Meyers, JP	1
Smyrk, TC	1
Julie, C	1
Zawadi, A	1
Tabernero, J	1
Mini, E	1
Goldberg, RM	2
Folprecht, G	1
Van Laethem, JL	1
Le Malicot, K	1
Sargent, DJ	1
Laurent-Puig, P	1
Sinicrope, FA	1
Wang, CH	2
Tokoro, T	1
Nakamura, K	1
Hirose, A	1
Nakanuma, S	1
Okamoto, K	1
Kinoshita, J	1
Makino, I	1
Hayashi, H	1
Oyama, K	1
Miyashita, T	1
Tajima, H	1
Takamura, H	1
Ninomiya, I	1
Fushida, S	1
Ohta, T	1
Cloughesy, TF	1
Landolfi, J	1
Vogelbaum, MA	1
Ostertag, D	2
Elder, JB	1
Bloomfield, S	1
Carter, B	1
Chen, CC	1
Kalkanis, SN	2
Kesari, S	1
Lai, A	1
Lee, IY	1
Liau, LM	1
Mikkelsen, T	2
Nghiemphu, P	1
Piccioni, D	1
Accomando, W	1
Diago, OR	1
Hogan, DJ	1
Gammon, D	1
Kasahara, N	2
Kheoh, T	1
Jolly, DJ	2
Gruber, HE	2
Das, A	1
Walbert, T	2
Lakkadwala, S	1
Singh, J	1
Takemoto, K	1
Miyahara, N	1
Chikuie, N	1
Hamamoto, T	1
Ishino, T	1
Ueda, T	1
Takeno, S	1
Kazlauskas, A	1
Darinskas, A	1
Meškys, R	1
Tamašauskas, A	1
Urbonavičius, J	1
Sun, Y	1
Wu, X	1
Lin, H	1
Lu, X	1
Huang, Y	1
Chi, P	1
Schaller, G	1
Kang, W	1
Seol, HJ	1
Seong, DH	1
Kim, J	1
Kim, Y	1
Kim, SU	3
Nam, DH	1
Joo, KM	1
Naskhletashvili, DR	1
Gorbunova, VA	1
Moskvina, EA	1
Pierga, JY	3
Bidard, FC	1
Cropet, C	3
Tresca, P	1
Dalenc, F	2
Romieu, G	2
Campone, M	4
Mahier Aït-Oukhatar, C	1
Le Rhun, E	3
Gonçalves, A	3
Leheurteur, M	2
Dômont, J	2
Gutierrez, M	2
Curé, H	2
Ferrero, JM	2
Labbe-Devilliers, C	2
Bachelot, T	4
Wadhwa, R	1
Taketa, T	1
Correa, AM	1
Sudo, K	1
Campagna, MC	1
Blum, MA	1
Komaki, R	1
Skinner, H	1
Lee, JH	2
Bhutani, MS	1
Weston, B	1
Maru, DM	1
Rice, DC	1
Swisher, S	1
Hofstetter, WL	1
Ajani, JA	1
Kim, EY	1
Yechieli, R	1
Kim, JK	1
Rock, J	1
Rosenblum, M	1
Ryu, S	1
Shimada, K	1
Ishikawa, T	1
Yoneyama, S	1
Kita, K	1
Narui, K	1
Sugae, S	1
Shimizu, D	1
Tanabe, M	1
Sasaki, T	2
Chishima, T	1
Ichikawa, Y	1
Endo, I	1
Gmeiner, WH	1
Lema-Tome, C	1
Gibo, D	1
Jennings-Gee, J	1
Milligan, C	1
Debinski, W	1
Şendur, MA	1
Uncu, D	1
Zengin, N	1
Cao, KI	1
Kirova, YM	2
Tanaka, H	1
Jotoku, H	1
Takasaki, M	1
Ibayashi, Y	1
Watanabe, K	1
Takahashi, M	1
Kutlu, C	1
Çakmak, AS	1
Gümüşderelioğlu, M	1
Morikawa, A	1
Peereboom, DM	1
Thorsheim, HR	1
Samala, R	1
Balyan, R	1
Murphy, CG	1
Lockman, PR	1
Simmons, A	1
Weil, RJ	1
Tabar, V	1
Steeg, PS	1
Smith, QR	1
Seidman, AD	1
Arslan, C	1
Dizdar, O	1
Altundag, K	1
De Iuliis, F	1
Salerno, G	1
Taglieri, L	1
Vicinanza, R	1
Lanza, R	1
Scarpa, S	1
Niravath, P	1
Tham, YL	1
Wang, T	1
Rodriguez, A	1
Foreman, C	1
Hilsenbeck, SG	1
Elledge, R	1
Rimawi, M	1
Cinar, P	1
Calkins, SM	1
Venook, AP	1
Kelley, RK	1
Zhang, J	1
Zhang, L	1
Yan, Y	1
Li, S	1
Xie, L	1
Zhong, W	1
Lv, J	1
Zhang, X	2
Bai, Y	1
Cheng, Z	1
Leshem, Y	1
Fennig, S	1
Talianski, E	1
Greenberg, G	1
Wolf, I	1
Taguchi, Y	1
Takashima, S	1
Tanaka, K	1
Lee, A	1
Go, SI	1
Lee, WS	1
Lee, US	1
Kim, MJ	1
Kang, MH	1
Lee, GW	1
Kim, HG	1
Kang, JH	1
Jeon, KN	1
Cho, JM	1
Bergen, ES	1
Berghoff, AS	1
Rudas, M	2
Preusser, M	2
Bartsch, R	3
Nishimura, J	1
Noda, E	1
Kitayama, K	1
Nomura, S	1
Teraoka, H	1
Nishino, H	1
Hirakawa, K	1
Shibasaki, M	1
Tanabe, A	1
Toda, T	1
Sakata, H	1
Ijichi, M	1
Kusaka, K	1
Bandai, Y	1
Grill, J	1
Wright, KD	1
Daryani, VM	1
Turner, DC	1
Onar-Thomas, A	1
Boulos, N	2
Orr, BA	1
Gilbertson, RJ	2
Stewart, CF	2
Gajjar, A	2
Muroya, T	1
Wajima, N	1
Akasaka, H	1
Ichinohe, D	1
Umetsu, S	1
Yoshida, T	1
Wakasa, Y	1
Hakamada, K	1
Zielinski, V	1
Laban, S	1
Tribius, S	1
Schafhausen, P	1
Veldhoen, S	1
Knecht, R	1
Clauditz, T	1
Muenscher, A	1
Sagara, A	1
Igarashi, K	1
Otsuka, M	1
Karasawa, T	1
Gotoh, N	1
Narita, M	2
Kuzumaki, N	1
Kato, Y	2
Hizawa, K	1
Nagata, Y	1
Taniguchi, M	1
Nakamori, M	1
Matsumoto, T	1
Iida, M	1
Recchia, F	1
Candeloro, G	1
Necozione, S	1
Bratta, M	1
Bisegna, R	1
Rea, S	1
Baki, M	1
Chargari, C	1
Diéras, V	4
Castro Pena, P	1
Pena, PC	1
Campana, F	1
Cottu, PH	1
Pierga, J	1
Fourquet, A	1
Lin, NU	3
Paul, D	1
Lossignol, D	1
Christodoulou, C	1
Stemmler, HJ	2
Roché, H	1
Liu, MC	1
Greil, R	2
Ciruelos, E	1
Loibl, S	1
Gori, S	2
Wardley, A	2
Yardley, D	1
Brufsky, A	1
Blum, JL	1
Rubin, SD	2
Dharan, B	1
Steplewski, K	2
Zembryki, D	3
Oliva, C	2
Roychowdhury, D	1
Paoletti, P	1
Winer, EP	2
Arifin, DY	1
Lee, KY	1
Truchuelo, M	1
Vano-Galvan, S	1
Pérez, B	1
Muñoz-Zato, E	1
Jaén, P	1
Capri, G	1
Chang, J	1
Chen, SC	1
Conte, P	1
Cwiertka, K	1
Jerusalem, G	1
Jiang, Z	1
Johnston, S	1
Kaufman, B	2
Link, J	1
Ro, J	2
Schütte, J	1
Parikh, R	1
Preston, A	1
Rosenlund, J	1
Selzer, M	1
De Placido, S	1
Iijima, S	1
Makari, Y	1
Kato, T	2
Ooshima, S	1
Hoshi, M	1
Doi, T	1
Miyake, Y	1
Sakamoto, T	1
Kato, A	1
Miyo, M	1
Kurokawa, E	1
Kikkawa, N	1
Pikó, B	1
Sutherland, S	1
Ashley, S	1
Miles, D	1
Chan, S	1
Davidson, N	1
Bhatti, R	1
Shehata, M	1
Nouras, H	1
Camburn, T	1
Johnston, SR	1
Rughani, AI	1
Lin, C	1
Tranmer, BI	1
Wilson, JT	1
Grunda, JM	1
Fiveash, J	1
Palmer, CA	1
Cantor, A	1
Fathallah-Shaykh, HM	1
Nabors, LB	2
Johnson, MR	2
Chang, DY	1
Yoo, SW	1
Hong, Y	1
Kim, S	2
Kim, SJ	1
Yoon, SH	1
Cho, KG	2
Paek, SH	1
Lee, YD	1
Kim, SS	1
Suh-Kim, H	1
Hlavaty, J	2
Jandl, G	1
Liszt, M	1
Petznek, H	1
König-Schuster, M	1
Sedlak, J	1
Egerbacher, M	1
Weissenberger, J	1
Salmons, B	1
Günzburg, WH	1
Renner, M	1
Gilbert, MR	1
Groves, MD	1
Puduvalli, VK	1
Yung, WK	5
Conrad, CA	1
Bobustuc, GC	1
Colman, H	1
Hsu, SH	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)[NCT06141369]		21 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Efficacy and Safety of Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin in pMMR/MSS Locally Advanced Middle and Low Rectal Cancer: An Open, Multi-center, Prospective, Single-arm Phase II Clinical Study[NCT06056804]	Phase 2	20 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)[NCT02563002]	Phase 3	307 participants (Actual)	Interventional	2015-11-30	Completed
Combination of Sintilimab，Celecoxib and Regorafenib in Mismatch Repair (MMR) Proficient Refractory Advanced Colorectal Cancer Without Liver Metastasis：a Single Arm Phase II SINCERE Study.[NCT05933980]	Phase 2	33 participants (Anticipated)	Interventional	2023-08-20	Not yet recruiting
Multi-center, Non-interventional, Prospective Registry Study on the Treatment of Solid Tumors With Mismatch Repair Deficiency or Microsatellite Instability[NCT06004713]		190 participants (Anticipated)	Observational	2023-10-07	Recruiting
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin[NCT05504252]	Phase 2	80 participants (Anticipated)	Interventional	2022-10-05	Recruiting
A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer[NCT00079274]	Phase 3	3,397 participants (Actual)	Interventional	2004-02-29	Completed
A Phase 1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC[NCT01470794]	Phase 1	58 participants (Actual)	Interventional	2012-02-29	Completed
A Multicenter Phase II Clinical Trial Assessing the Efficacy of the Combination of Lapatinib and Capecitabine in Patients With Non Pretreated Brain Metastasis From HER2 Positive Breast Cancer[NCT00967031]	Phase 2	45 participants (Actual)	Interventional	2009-04-30	Completed
TS Overexpression in SCLC: Mechanism and Therapeutic Targeting[NCT03741829]		12 participants (Actual)	Observational	2017-06-14	Completed
Clinical Study to Assess Entry of Chemotherapeutic Agents Into Brain Metastases in Women With Breast Cancer[NCT00795678]		10 participants (Actual)	Observational	2008-09-30	Completed
Phase 1 Trial of Tucatinib, Trastuzumab, and Capecitabine With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From HER-2 Positive Breast Cancer[NCT05553522]	Phase 1	40 participants (Anticipated)	Interventional	2023-09-18	Recruiting
A Phase II Study of Eribulin in Brain Metastases From HER2-negative Breast Cancer Pre-treated With Anthracyclines and Taxanes[NCT03637868]	Phase 2	0 participants (Actual)	Interventional	2019-02-26	Withdrawn (stopped due to no enrollment)
Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases[NCT01934894]	Phase 2	11 participants (Actual)	Interventional	2014-05-31	Terminated (stopped due to Study was terminated due to lack of significant signal of efficacy)
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy[NCT00263588]	Phase 2	242 participants (Actual)	Interventional	2005-12-02	Completed
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy[NCT00437073]	Phase 2	22 participants (Actual)	Interventional	2007-05-31	Terminated (stopped due to Lapatinib-topotecan arm enrollment closed early per protocol amendment 2. Then enrollment into remaining arm terminated due to operational issues.)
A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma[NCT01156584]	Phase 1	54 participants (Actual)	Interventional	2010-07-31	Completed
A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extende[NCT01985256]	Phase 1	17 participants (Actual)	Interventional	2014-02-28	Completed
An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects With ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer[NCT00338247]		0 participants	Expanded Access	2006-07-31	Approved for marketing
Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320]	Phase 2	200 participants (Actual)	Interventional	2015-10-05	Active, not recruiting
Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028]	Phase 2	100 participants (Actual)	Interventional	2011-06-30	Completed
A Phase III Randomized Controlled Trial of Prophylactic Cranial Irradiation in Patients With Advanced Triple Negative Breast Cancer Who Had a Response to First Line Chemotherapy[NCT02448576]		326 participants (Anticipated)	Interventional	2017-08-31	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who discontinued study treatment due to an AE was presented for the first course study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months

Number of Participants Who Experienced an Adverse Event (AE)

Intervention	Participants (Count of Participants)
Pembrolizumab	21
Standard of Care (SOC)	20

An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who experienced at least one AE was presented for the first course study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months

Overall Response Rate (ORR) Per RECIST1.1 as Assessed by Central Imaging Vendor

Intervention	Participants (Count of Participants)
Pembrolizumab	149
Standard of Care (SOC)	142

ORR was defined as the percentage of the participants who experienced a Complete Response (CR; disappearance of all target lesions) or a Partial Response (PR; at least a 30% decrease in the sum of diameters of target lesions) and was assessed using RECIST 1.1 as assessed by the central imaging vendor. The percentage of participants who experienced a CR or PR was presented for the first course of study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months

Overall Survival (OS)

Intervention	Percentage of Participants (Number)
Pembrolizumab	45.1
Standard of Care (SOC)	33.1

OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of analysis were censored at the date of last known contact. HR and associated 95% CIs from a Cox proportional hazard model with Efron's method of tie handling and with a single treatment covariate was presented for the first course study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months

Progression-Free Survival (PFS) Per RECIST1.1 As Assessed by Central Imaging Vendor

Intervention	Months (Median)
Pembrolizumab	NA
Standard of Care (SOC)	36.7

PFS was defined as the time from randomization to the first documented disease progression (PD) per RECIST 1.1 based on blinded central imaging vendor review or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Hazards ratio (HR) and associated 95% confidence intervals (CIs) from a Cox proportional hazard model with Efron's method of tie handling and with a single treatment covariate was presented for the first course study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months

Disease-free Survival (Arms A and D: Mutant KRAS Patients)

Intervention	Months (Median)
Pembrolizumab	16.5
Standard of Care (SOC)	8.2

"A secondary endpoint for this study was to investigate the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years

Disease-free Survival (Arms A and D: Wild-type KRAS Patients)

Intervention	percentage of participants (Number)
Mutant KRAS Arm A	67.1
Mutant KRAS Arm D	65.0

"The primary endpoint for this study was to compare the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years

Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Mutant KRAS Patients)

Intervention	percentage of participants (Number)
Wild-type KRAS Arm A	74.6
Wild-type KRAS Arm D	71.5

Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event-free rates (percentage) are report below for mutant KRAS patients. (NCT00079274)
Timeframe: Up to 3 years

Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Wild-type KRAS Patients)

Intervention	percentage of participants (Number)
Mutant KRAS Arm A	87.9
Mutant KRAS Arm D	82.7

Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event free rates (percentage) are reported below for Wild-type KRAS Patients. (NCT00079274)
Timeframe: Up to 3 years

Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Mutant KRAS Patients)

Intervention	percentage of participants (Number)
Wild-type KRAS Arm A	87.3
Wild-type KRAS Arm D	85.6

The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years

Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Wild-type KRAS Patients)

Intervention	percentage of patients (Number)
Mutant KRAS Arm A	55.6
Mutant KRAS Arm D	72.3

The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years

CNS Clinical Benefit Response

Intervention	percentage of patients (Number)
Wild-type KRAS Arm A	51.1
Wild-type KRAS Arm D	73.3

The number of patients with Complete Response, Partial Response or Stable Disease extending beyond 6 months (CR+PR+SD ≥ 6 months), determined by RECIST v1.1. CR=disappearance of all target and non-target lesions; PR=at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter AND an absolute decrease of at least 5mm in at least one target lesion; SD=Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of the longest diameter since the treatment started. (NCT01934894)
Timeframe: every 6 weeks thru cycle 8, and every 3 cycles thereafter until treatment discontinuation, projected 1 year

CNS Objective Response

Intervention	Participants (Count of Participants)
Dose Level 1 (20 mg/m^2 Cabazitaxel + Lapatinib)	2
Dose Level 2 (25 mg/m^2 Cabazitaxel + Lapatinib)	0

The number of patients with Complete and Partial Response (CR+PR) of CNS lesions assessed per modified RECIST Criteria for Evaluation of Intracranial Disease. CR=disappearance of all target and non-target lesions; PR=at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter AND an absolute decrease of at least 5mm in at least one target lesion. (NCT01934894)
Timeframe: every 6 weeks thru cycle 8, then every 9 weeks until treatment discontinuation, projected 1 year

Extra-Cranial Objective Response

Intervention	Participants (Count of Participants)
Dose Level 1 (20 mg/m^2 Cabazitaxel + Lapatinib)	0
Dose Level 2 (25 mg/m^2 Cabazitaxel + Lapatinib)	0

The number of participants having Complete and Partial Responses (CR+PR) of extra-cranial lesions assessed per RECIST v1.1 Criteria. CR=disappearance of all target and non-target lesions; PR=at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter AND an absolute decrease of at least 5mm in at least one target lesion. (NCT01934894)
Timeframe: every 6 weeks for 8 cycles, then every 9 weeks until treatment discontinuation, up to 1 year

Maximum Tolerated Dose of Cabazitaxel With Lapatinib

Intervention	Participants (Count of Participants)
Dose Level 1 (20 mg/m^2 Cabazitaxel + Lapatinib)	0
Dose Level 2 (25 mg/m^2 Cabazitaxel + Lapatinib)	0

The maximum tolerated dose (MTD) of cabazitaxel and lapatinib will be determined as the highest dose at which ≤1 of 6 patients experiences a dose-limiting toxicity (DLT) assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0. A listing of DLTs are reported in the subsequent Primary Outcome Measure. (NCT01934894)
Timeframe: weekly for 3 weeks

Number of Participants Who Experience Dose-Limiting Toxicities (DLTs) as a Measure of Safety

Intervention	mg/m^2 of cabazitaxel + lapatinib (Number)
Cabazitaxel and Lapatinib	NA

During the safety lead-in, a standard 3+3 dose escalation design is used to determine the maximum tolerated dose (MTD) of cabazitaxel with lapatinib. The MTD would be determined by the highest dose at which ≤1 of 6 patients experiences a dose-limiting toxicity (DLT) during 1 cycle (21 days) of therapy. If 2 of 6 patients within a dose level experiences a DLT, that dose level would be defined as exceeding the MTD and the previous dose level would be evaluated. DLTs are assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0. (NCT01934894)
Timeframe: weekly for 3 weeks

Duration of Central Nervous System (CNS) Objective Response

Intervention	Participants (Count of Participants)
	febrile neutropenia	neutropenia	diarrhea	septic shock
Dose Level 1	0	0	0	1
Dose Level 2	1	1	2	0

"The duration of CNS objective response, defined as the time from first CNS~Objective response until tumor progression at any site or death due to any cause.~A CNS objective response was defined as either a Complete Response (CR) or Partial Response (PR), as assessed by volumetric analysis of magnetic resonance imaging (MRI), provided there was no progression of systemic disease outside of the CNS, increasing steroid requirements, or worsening of tumor-related neurological signs or symptoms." (NCT00263588)
Timeframe: time from baseline to data cutoff (25 Sept 2007); approximately 2 years

Overall Survival (OS)

Intervention	months (Median)
Cohort A	2.43
Cohort B	1.58

Overall survival (OS) defined as the time from initiation of investigational product to death due to any cause. (NCT00263588)
Timeframe: time from baseline to data cutoff (25 Sept 2007); approximately 2 years

Percentage of Patients With CNS Disease Control (Complete Response, Partial Response or Stable Disease) at 6 Months of Lapatinib Therapy

Intervention	months (Median)
Cohort A	10.78
Cohort B	5.82

The CNS disease control rate, defined as the percentage of subjects with CR, PR or stable disease at Week 24 (NCT00263588)
Timeframe: from Start of lapatinib to 6 months

The Percentage of Participants With Central Nervous System (CNS) Objective Response Rate - Response Rate (CR + PR)

Intervention	percentage of participants (Number)
Cohort A	9
Cohort B	2

Summary of CNS Objective Response (the Complete Response + Partial Response) (NCT00263588)
Timeframe: time from baseline to data cutoff (25 Sept 2007); approximately 2 years

Time to Progression (TTP) at Any Site

Intervention	percentage of participants (Number)
Cohort A	6
Cohort B	6

Summary of Kaplan-Meier Estimates for Progression Free Survival at Any Site (NCT00263588)
Timeframe: time from baseline to data cutoff (25 Sept 2007); approximately 2 years

Percentage of Participants With Improvement in Neurological Signs and Symptoms (NSS) Measured Using the Neurological Examination Worksheet

Intervention	months (Median)
Cohort A	2.60
Cohort B	1.87

Physician-reported NSS worksheet is derived from 13 AEs and measured by NCI CTCAE v3.0 grouped into 7 categories: level of consciousness, neurological symptoms, cranial nerves, language, strength, sensation, & ataxia. Improvement of NSS required: Decrease by 1 or more grades from baseline of any tumor-related NSS, with confirmation at least 4 wks later, No development or worsening in any tumor-related NSS during interval, No radiographic evidence of CNS progression (assessed by volumetric MRI) or systemic (non-CNS) progression (assessed by RECIST) during interval, Stable or decreasing steroids during interval as defined by GSK equivalent doses of an alternative corticosteroid or a dose increase for non-tumor related reasons didn't constitute a steroid increase. Improvement in any non-tumor associated NSS didn't constitute improvement in NSS. Neurological exam, using Neurological Examination Worksheet was assessed at baseline & each 4 wks. Categories below are not mutually exclusive. (NCT00263588)
Timeframe: time from baseline to data cutoff (25 Sept 2007); approximately 2 years

Percentage of Subjects With a CNS Objective Response or Improvement in Baseline Neurological Signs and Symptoms (NSS)

Intervention	Participants (Count of Participants)
	Subjects with NSS improvement	>=20% volumetric reduction of lesion	any volumetric reduction of lesion	volumetric increase or withdrew
Cohorts A and B	24	8	14	9

Summary of Proportion of Subjects with a CNS Objective Response or Improvement in Baseline NSS (NCT00263588)
Timeframe: baseline and weeks 8, 16, 24, 32, 40, 48

Primary Cause of Death

Intervention	percentage of participants (Number)
	week 8	week 16	week 24	week 32	week 40	week 48
Cohort A	23	2	8	17	0.0	0.0
Cohort B	14	8	11	0.0	0.0	0.0

Summary of Overall All-cause mortality (Main Study and Extension) (NCT00263588)
Timeframe: time from baseline to data cutoff (25 Sept 2007); approximately 2 years

Summary of Site of First Progression

Intervention	Participants (Count of Participants)
	Disease under study	Other
Cohort A	74	4
Cohort B	124	4

baseline to time of disease progression or death (NCT00263588)
Timeframe: time from baseline to data cutoff (25 Sept 2007); approximately 2 years

The Number of Participants With Central Nervous System (CNS) Best Overall Response

Intervention	Participants (Count of Participants)
	CNS progression	Non-CNS prgression	CNS and Non-CNS progression
Cohort A	69	1	12
Cohort B	72	10	36

"Summary of CNS Objective Response (Lapatinib Monotherapy - MITT Population)~Response to lapatinib in patients with progressive brain metastases from ErbB2-overexpressing breast cancer.~The primary indicator of drug efficacy was CNS objective response rate. A CNS objective response was defined as either a Complete response (CR) or Partial response (PR), as assessed by volumetric analysis of brain Magnetic resonance imaging (MRI), provided there was no progression of systemic disease outside of the CNS, increasing steroid requirements, or worsening of Neurological signs and symptoms (NSS)~A CNS objective response rate was defined as a 50% volumetric reduction in sum of CNS target lesions, with no new or progressive CNS or non-CNS lesions, no increases in tumor-related steroid requirements and no worsening of neurological signs or symptoms" (NCT00263588)
Timeframe: time from baseline to data cutoff (25 Sept 2007); approximately 2 years

Number of Participants With the Indicated Central Nervous System (CNS) Objective Response (OR)

Intervention	Participants (Count of Participants)
	Complete response (CR)	Partial response (PR)	Stable disease (SD)	Progressive disease (PD)	Unknown
Cohort A	0	6	40	40	8
Cohort B	0	9	46	70	18

CNS OR is defined as the number of participants with either a complete response (CR) or partial response (PR) as assessed by volumetric analysis of brain magnetic resonance imaging (MRI) and Response Evaluation Criteria In Solid Tumors (RECIST). CR: complete resolution of all evaluable and non-evaluable brain metastases; PR: =>50% reduction in the volumetric sum of all evaluable brain metastases compared to baseline. (NCT00437073)
Timeframe: From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

Number of Participants With the Indicated CNS Responses

Intervention	participants (Number)
Lapatinib Plus Capecitabine	5
Lapatinib Plus Topotecan	0

"CNS responses were assessed by volumetric (V) analysis of brain MRI and RECIST. CR: complete resolution of all evaluable and non-evaluable brain metastases (BMs). PR: =>50% reduction in the V sum of all evaluable BMs compared to baseline. A response of Other was used for participants who discontinued the study prior to the first efficacy assessment. Stable Disease (SD): disease that does not meet CR, PR, or CNS progression criteria. Progressive disease (PD): a requirement for a new steroid or an increasing steroid dose for the treatment of worsening neurological signs/symptoms due to BMs." (NCT00437073)
Timeframe: From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

Article	Year
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 03-10, Volume: 40, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Colonic Neo	2022
Versatile use of Carmofur: A comprehensive review of its chemistry and pharmacology. Drug development research, 2022, Volume: 83, Issue:7 Topics: Antineoplastic Agents; Brain Neoplasms; Child; Colorectal Neoplasms; COVID-19; Fluorouracil; Humans	2022
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. JAMA oncology, 2018, Mar-01, Volume: 4, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brai	2018
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2014, Volume: 18, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barri	2014
Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:12 Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Deox	2014
[A case of phenytoin intoxication caused by interaction between phenytoin and capecitabine]. Brain and nerve = Shinkei kenkyu no shinpo, 2015, Volume: 67, Issue:2 Topics: Adult; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Capecitabine; Deoxycytidine; Drug In	2015
Management of sinonasal undifferentiated carcinoma with intracerebral invasion: Clinical experience at a single institution and review of the literature. Ear, nose, & throat journal, 2016, Volume: 95, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Chemoradiotherapy	2016
[Lapatinib treatment-option in trastuzumab-resistant breast cancer]. Magyar onkologia, 2009, Volume: 53, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com	2009
New insights and emerging therapies for breast cancer brain metastases. Oncology (Williston Park, N.Y.), 2012, Volume: 26, Issue:7 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecit	2012
[Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies]. Bulletin du cancer, 2013, Jan-01, Volume: 100, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro	2013
Chemotherapy for breast cancer brain metastases. Onkologie, 2002, Volume: 25, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cisplatin; Clinic	2002
Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. Gynecologic oncology, 2004, Volume: 94, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Deoxycytidine; Ep	2004
[Effects of biochemical modulation chemotherapy with CDDP and 5-FU on metastatic brain tumor from lung cancer]. No shinkei geka. Neurological surgery, 1997, Volume: 25, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispla	1997
Can neural stem cells be used to track down and destroy migratory brain tumor cells while also providing a means of repairing tumor-associated damage? Proceedings of the National Academy of Sciences of the United States of America, 2000, Nov-07, Volume: 97, Issue:23 Topics: Animals; Brain Neoplasms; Cell Movement; Combined Modality Therapy; Cytosine Deaminase; Flucytosine;	2000
Chemotherapy in the treatment of malignant brain tumors. Advances in neurology, 1975, Volume: 13 Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cyclophosphami	1975
The biologic basis of malignant brain tumor therapy. Advances in neurology, 1976, Volume: 15 Topics: Animals; BCG Vaccine; Brain Neoplasms; Carcinoma, Hepatocellular; Culture Techniques; DNA, Neoplasm;	1976
[The state of hormone and chemotherapy in breast neoplasms]. Schweizerische medizinische Wochenschrift, 1978, Sep-02, Volume: 108, Issue:35 Topics: Androgens; Brain Neoplasms; Breast Neoplasms; Castration; Cyclophosphamide; Doxorubicin; Drug Therap	1978
Individual cell biology: basis and prospects for a rational cancer chemotherapy. Archiv fur Geschwulstforschung, 1977, Volume: 47, Issue:8 Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cell Cycle; Chromosome Aberrations; Cyclophospham	1977
[Chemotherapy of cancer of the breast]. Ginecologia y obstetricia de Mexico, 1977, Volume: 42, Issue:252 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide;	1977
Chemotherapy of malignant gliomas: studies of the BTCG. Revue neurologique, 1992, Volume: 148, Issue:6-7 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Mod	1992
Chemotherapy for glioblastoma multiforme. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, 1991, Volume: 23, Issue:1 Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cisplatin; Fluorouracil; Humans; Methotrexate; N	1991
Chemotherapy of primary brain tumors. Neurologic clinics, 1985, Volume: 3, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Brain Stem; Child; Efl	1985
Principles of brain tumor chemotherapy. Seminars in oncology, 1986, Volume: 13, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier;	1986
Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. Seminars in oncology, 1986, Volume: 13, Issue:1 Topics: Antineoplastic Agents; Autoradiography; Biological Transport; Blood-Brain Barrier; Brain Neoplasms;	1986
Neurologic complications of systemic cancer. Neurologic clinics, 1985, Volume: 3, Issue:4 Topics: Arachnoid; Bacterial Infections; Brain; Brain Neoplasms; Cerebrovascular Disorders; Cisplatin; Disse	1985
Chemotherapy of brain tumors. Progress in experimental tumor research, 1972, Volume: 17 Topics: Adult; Antineoplastic Agents; Azaguanine; Bleomycin; Brain Neoplasms; Child; Cyclophosphamide; Drug	1972

Article	Year
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi	2020
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro-oncology, 2018, 09-03, Volume: 20, Issue:10 Topics: Antimetabolites; Brain Neoplasms; Combined Modality Therapy; Cytosine Deaminase; Drug Synergism; Flu	2018
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cape	2013
A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer. The oncologist, 2015, Volume: 20, Issue:1 Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-F	2015
Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. Neuro-oncology, 2015, Volume: 17, Issue:12 Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Brain Neoplasms; Child; Child, Preschool; Dose-R	2015
Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. American journal of clinical oncology, 2008, Volume: 31, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone	2008
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-15, Volume: 15, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabi	2009
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Bre	2010
Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, May-15, Volume: 16, Issue:10 Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Capecitabine; Combined Mo	2010
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. Journal of neuro-oncology, 2011, Volume: 105, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabi	2011
Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. BMC cancer, 2012, Jul-28, Volume: 12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cape	2012
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. The Lancet. Oncology, 2013, Volume: 14, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cape	2013
Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Socie Breast cancer (Tokyo, Japan), 2014, Volume: 21, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai	2014
Implantable drug-releasing biodegradable microspheres for local treatment of brain glioma. Acta neurochirurgica. Supplement, 2003, Volume: 88 Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Biological Availability; Brain Neoplasms; C	2003
Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. Cancer, 2004, Jan-15, Volume: 100, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Delivery Systems; Drug Implant	2004
High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer. Bone marrow transplantation, 2004, Volume: 34, Issue:7 Topics: Adult; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy	2004
Effectiveness of novel combination chemotherapy, consisting of 5-fluorouracil, vincristine, cyclophosphamide and etoposide, in the treatment of low-grade gliomas in children. Journal of neuro-oncology, 2006, Volume: 80, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool	2006
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer, 2006, Sep-15, Volume: 107, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cape	2006
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-01, Volume: 25, Issue:25 Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast	2007
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Br	2008
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. Oncology, 2007, Volume: 73, Issue:1-2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin	2007
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979. Cancer treatment reports, 1981, Volume: 65 Suppl 2 Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera	1981
A phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults. Journal of neuro-oncology, 1995, Volume: 23, Issue:3 Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Female; Fluorouracil; Glioblastoma; Glioma; Humans; Infus	1995
Cisplatin-5-fluorouracil in small cell lung cancer. A phase II study in 109 patients. Lung cancer (Amsterdam, Netherlands), 1994, Volume: 11, Issue:3-4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell;	1994
A phase 1-2 trial of superselective carboplatin, low-dose infusional 5-fluorouracil and concurrent radiation for high-grade gliomas. American journal of clinical oncology, 1995, Volume: 18, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat	1995
Radiosensitization with carotid intra-arterial bromodeoxyuridine +/- 5-fluorouracil biomodulation for malignant gliomas. Neurology, 1994, Volume: 44, Issue:9 Topics: Adult; Aged; Brain Neoplasms; Bromodeoxyuridine; Fluorouracil; Glioma; Humans; Infusions, Intra-Arte	1994
Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas. Journal of neuro-oncology, 1993, Volume: 15, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined	1993
Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor. Journal of neuro-oncology, 1996, Volume: 30, Issue:3 Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Astrocytoma; Brain Neoplasms; Female; Fluor	1996
Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. British journal of cancer, 1996, Volume: 74, Issue:12 Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth	1996
[Effects of biochemical modulation chemotherapy with CDDP and 5-FU on metastatic brain tumor from lung cancer]. No shinkei geka. Neurological surgery, 1997, Volume: 25, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispla	1997
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:3 Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neop	1997
Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma. American journal of clinical oncology, 1997, Volume: 20, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phyt	1997
Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study. Cancer, 1999, Jul-15, Volume: 86, Issue:2 Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Biodegradation, Environmental; Brain Neopl	1999
Response and progression in recurrent malignant glioma. Neuro-oncology, 1999, Volume: 1, Issue:4 Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Alitretinoin; Antineoplastic Combine	1999
Chemotherapy: adjuvant to surgery and radiation therapy. Seminars in oncology, 1975, Volume: 2, Issue:1 Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Fluorouracil; Glioma;	1975
[Chemotherapy of metastasizing breast cancers. Indications and results]. Deutsche medizinische Wochenschrift (1946), 1975, Jan-10, Volume: 100, Issue:2 Topics: Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fema	1975
Chemotherapy of malignant gliomas: studies of the BTCG. Revue neurologique, 1992, Volume: 148, Issue:6-7 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Mod	1992
Phase I/II trial of superselective arterial 5-FU infusion with concomitant external beam radiation for patients with either anaplastic astrocytoma or glioblastoma multiforme. American journal of clinical oncology, 1991, Volume: 14, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Drug Admini	1991
4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Bon	1991
An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer. Japanese journal of clinical oncology, 1991, Volume: 21, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispla	1991
The role of intraluminal radiotherapy and concurrent 5-fluorouracil infusion in the management of carcinoma esophagus: a pilot study. Journal of surgical oncology, 1991, Volume: 47, Issue:3 Topics: Adult; Aged; Brachytherapy; Brain Neoplasms; Combined Modality Therapy; Deglutition Disorders; Esoph	1991
Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer. A Southwest Oncology Group Study. Cancer, 1989, Dec-15, Volume: 64, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; C	1989
Aggressive adriamycin-containing regimen (PM-FAC) in estrogen receptor-negative disseminated breast cancer. Results of a Southwest Oncology Group trial. Cancer, 1985, Nov-15, Volume: 56, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Clinical Trials a	1985
Second Joint Working Conference: National Cancer Institute Chemotherapy Program. Working session report: clinical trials. Cancer chemotherapy reports. Part 3, 1972, Volume: 3, Issue:1 Topics: Antineoplastic Agents; Blood Platelets; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic;	1972

fluorouracil and Brain Neoplasms

Research Excerpts

Research

Studies (286)

Authors

Clinical Trials (22)

Trial Overview

Trial Outcomes

Number of Participants Who Discontinued Study Treatment Due to an AE

Number of Participants Who Experienced an Adverse Event (AE)

Overall Response Rate (ORR) Per RECIST1.1 as Assessed by Central Imaging Vendor

Overall Survival (OS)

Progression-Free Survival (PFS) Per RECIST1.1 As Assessed by Central Imaging Vendor

Disease-free Survival (Arms A and D: Mutant KRAS Patients)

Disease-free Survival (Arms A and D: Wild-type KRAS Patients)

Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Mutant KRAS Patients)

Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Wild-type KRAS Patients)

Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Mutant KRAS Patients)

Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Wild-type KRAS Patients)

CNS Clinical Benefit Response

CNS Objective Response

Extra-Cranial Objective Response

Maximum Tolerated Dose of Cabazitaxel With Lapatinib

Number of Participants Who Experience Dose-Limiting Toxicities (DLTs) as a Measure of Safety

Duration of Central Nervous System (CNS) Objective Response

Overall Survival (OS)

Percentage of Patients With CNS Disease Control (Complete Response, Partial Response or Stable Disease) at 6 Months of Lapatinib Therapy

The Percentage of Participants With Central Nervous System (CNS) Objective Response Rate - Response Rate (CR + PR)

Time to Progression (TTP) at Any Site

Percentage of Participants With Improvement in Neurological Signs and Symptoms (NSS) Measured Using the Neurological Examination Worksheet

Percentage of Subjects With a CNS Objective Response or Improvement in Baseline Neurological Signs and Symptoms (NSS)

Primary Cause of Death

Summary of Site of First Progression

The Number of Participants With Central Nervous System (CNS) Best Overall Response

Number of Participants With the Indicated Central Nervous System (CNS) Objective Response (OR)

Number of Participants With the Indicated CNS Responses

Reviews

Trials

Other Studies

Intervention	participants (Number)
	Complete response	Partial response	Stable Disease	Progressive Disease	Unknown	Other
Lapatinib Plus Capecitabine	0	5	6	2	0	0
Lapatinib Plus Topotecan	0	0	3	1	3	2